Creo Medical has conditionally raised £12m via an equity offering, with a retail offer for a further up to £5m underway, which alongside the cash expected to be received from the sale of a 51% share of Creo Europe, will be sufficient to see the company reach sustainable profitability based on our revised forecasts. Our model assumes the sale completes at the start of FY25 and cash is received at that time. As such our re-instated revenue forecasts are based on the sale of Core Creo devices, inco ....